Sanjay Popat brings context to the CheckMate 227 data in light of the currently available options for patients with treatment-naïve, advanced non-small-cell lung cancer, highlighting the key aspects physicians need to bear in mind when considering nivolumab plus ipilimumab for their patients (2:20).
Lizza Hendriks provides insight into two studies focusing on brain metastases in patients with non-small-cell lung cancer, the ASCEND-7 trial of ceritinib and an analysis of the genomic and epigenomic landscape of the metastases (4:26).
Ross Camidge comments on the advanced non-small-cell lung cancer research that caught his attention at the ESMO Congress 2019, including the FLAURA and CheckMate 227 overall survival data, and updates on brigatinib and lorlatinib (3:01).
Solange Peters discusses the implications of the CheckMate 227 findings for the front-line treatment of advanced non-small-cell lung cancer and outlines the key next steps (3:45).
Sanjay Popat reports on the trial pitting pembrolizumab against chemotherapy in relapsed malignant pleural mesothelioma and outlines possible strategies for taking immune checkpoint inhibitors forward (4:53).
Suresh Ramalingam presents the overall survival analysis of the FLAURA trial of osimertinib in EGFR mutation-positive, advanced non-small-cell lung cancer, and discusses the options after progression on the tyrosine kinase inhibitor (1:50).
WATCH | Eric Lim describes the findings of the VIOLET trial comparing video-assisted thoracoscopic lobectomy and open lobectomy for early-stage lung cancer (1:57).
WATCH | Raffaele Califano comments on the CASPIAN trial of front-line durvalumab plus chemotherapy in extensive-stage small-cell lung cancer, and puts the findings in context of the IMpower133 study of atezolizumab in the same setting (3:30).
WATCH | Stephen Lam discusses the interim findings from the International Lung Screen Trial indicating that changing eligibility criteria can improve identification of high-risk individuals (5:36).
WATCH | Ugo Pastorino discusses the bioMILD study, which investigates a lung cancer screening program that supplements low-dose computed tomography with a blood microRNA assay (3:09).
WATCH | Ramaswamy Govindan outlines the key findings of the non-small-cell lung cancer cohort of the phase I trial of the novel KRAS inhibitor AMG 510, and comments on the next steps for the research (5:34).
WATCH | Is first-line nivolumab–ipilimumab a feasible option for certain subgroups of advanced non-small-cell lung cancer patients, such as those with poor functional status? Fabrice Barlesi discusses the CheckMate 817 trial (3:32).
WATCH |Corey Langer describes the findings from the KEYNOTE-021 exploratory analysis of the relationship between response to pembrolizumab plus chemotherapy and tumor mutational burden in metastatic non-small-cell lung cancer patients (7:35).
WATCH |Advisory Board member Ross Camidge shares his top picks of the presentations at the 2019 World Conference on Lung Cancer, including the CASPIAN trial and the updated AMG 510 data (1:51).
Brian Baumann presents their comparative analysis of the adverse event profiles of proton and photon radiotherapy in nonmetastatic patients receiving chemoradiotherapy with curative intent for various solid tumors, including lung cancer (5:28).
Brain metastases are a common complication of lung cancer and are associated with significant morbidity and mortality. In these videos, Manmeet Ahluwalia provides a neuro-oncologist's perspective on managing lung cancer patients who develop these metastases.
This content collection was made possible by independent educational funding provided by AstraZeneca.
Mellisa Wheeler talks about how their mobile low dose-CT lung scanning unit – the Lung Bus – is helping to reach underserved populations in North Carolina, USA. She also comments on the issues of access to care and overscreening, and outlines the next steps (3:54).
ASCO expert David Graham tells us just why he thinks the 5-year survival data from the advanced non-small-cell lung cancer patients enrolled in the phase Ib KEYNOTE-001 trial are so remarkable (1:26).
Edward Garon presents the 5-year follow-up results of the advanced non-small-cell lung cancer cohort of the phase I KEYNOTE-001 trial of pembrolizumab monotherapy (4:12).